Comparative Pharmacology
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus KALLIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus KALLIGA.
CHLORPHENIRAMINE MALEATE vs KALLIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1 receptor antagonist; competitively blocks histamine at H1 receptors, preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, and smooth muscle contraction.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
4 mg orally every 4-6 hours, not to exceed 24 mg per day; or 10-20 mg intramuscularly or intravenously as a single dose, not to exceed 40 mg per day.
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
None Documented
None Documented
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life: 12-15 hours (prolonged in hepatic impairment).
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Renal: ~50% as metabolites; Fecal: negligible; Biliary: minor.
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine
Antihistamine
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."